Cargando…

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asano, Hiroto, Tian, Yu-Shi, Hatabu, Asuka, Takagi, Tatsuya, Ueda, Mikiko, Ikeda, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630381/ https://www.ncbi.nlm.nih.gov/pubmed/37935702 http://dx.doi.org/10.1038/s41598-023-44142-2

Ejemplares similares

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
por: Robottom, Bradley J
Publicado: (2011)

ABUSE OF MONOAMINE OXIDASE INHIBITORS
por: Ananth, Jambur, et al.
Publicado: (1995)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
por: Chiuccariello, Lina, et al.
Publicado: (2015)

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
por: Tan, Yu-Yan, et al.
Publicado: (2022)

Amphetamine Derivatives as Monoamine Oxidase Inhibitors
por: Reyes-Parada, Miguel, et al.
Publicado: (2020)

Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022)

Knowledge, attitudes, and practices toward COVID-19 among university students in Japan and associated factors: An online cross-sectional survey
por: Hatabu, Asuka, et al.
Publicado: (2020)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

3-Coumaranone derivatives as inhibitors of monoamine oxidase
por: Van Dyk, Adriaan S, et al.
Publicado: (2015)

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
por: Alborghetti, Marika, et al.
Publicado: (2019)

Parameters for Irreversible Inactivation of Monoamine Oxidase
por: Ramsay, Rona R., et al.
Publicado: (2020)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action
por: Rinaldi, Domiziana, et al.
Publicado: (2023)

Monoamine Oxidase B in Renal Cell Carcinoma
por: Hodorová, Ingrid, et al.
Publicado: (2018)

Cardiac monoamine oxidases: at the heart of mitochondrial dysfunction
por: Mialet-Perez, Jeanne, et al.
Publicado: (2020)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

Multiscale Modeling of Two-Photon Probes for Parkinson’s Diagnostics Based on Monoamine Oxidase B Biomarker
por: Murugan, N. Arul, et al.
Publicado: (2020)

2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors
por: Legoabe, Lesetja J, et al.
Publicado: (2015)

“Ping-pong gaze” secondary to monoamine oxidase inhibitor overdose
por: Attaway, Amy, et al.
Publicado: (2016)

Monoamine Reuptake Inhibitors in Parkinson's Disease
por: Huot, Philippe, et al.
Publicado: (2015)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

The role of the monoamine oxidase A gene in moderating the response to adversity and associated antisocial behavior: a review
por: Buades-Rotger, Macià, et al.
Publicado: (2014)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
por: Bai, Yang, et al.
Publicado: (2023)

Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease
por: Lieu, Christopher A., et al.
Publicado: (2013)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
por: Omar, N.E., et al.
Publicado: (2021)

Smoking Related Diseases: The Central Role of Monoamine Oxidase
por: Rendu, Francine, et al.
Publicado: (2011)

Androgen receptor and monoamine oxidase polymorphism in wild bonobos
por: Garai, Cintia, et al.
Publicado: (2014)

Inhibition of Monoamine Oxidase by Stilbenes from Rheum palmatum
por: Wei, Bo, et al.
Publicado: (2016)

Mitochondrial Monoamine Oxidase: Another Player in Pulmonary Hypertension?
por: Sommer, Natascha, et al.
Publicado: (2021)

Recent advances on the role of monoamine oxidases in cardiac pathophysiology
por: Kaludercic, Nina, et al.
Publicado: (2023)

Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
por: Löhle, Matthias, et al.
Publicado: (2011)

The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: meta-analysis of randomized controlled trials
por: Huang, Yao Hsien, et al.
Publicado: (2021)

Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors
por: Zarmouh, Najla O., et al.
Publicado: (2016)

A Peroxidase-linked Spectrophotometric Assay for the Detection of Monoamine Oxidase Inhibitors
por: Zhi, Kangkang, et al.
Publicado: (2016)

Monoamine oxidase A (MAO A) inhibitors decrease glioma progression
por: Kushal, Swati, et al.
Publicado: (2016)

The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase
por: Cloete, Stephanus J., et al.
Publicado: (2020)

Halogenated Coumarin–Chalcones as Multifunctional Monoamine Oxidase-B and Butyrylcholinesterase Inhibitors
por: Rehuman, Nisha Abdul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5f9nll97slgndp36sd27knhgat